Poxel S.A. (EPA: POXEL)

Market Cap	12.44M
Revenue (ttm)	1.98M
Net Income (ttm)	-35.09M
Shares Out	53.29M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,390
Open	0.235
Previous Close	0.234
Day's Range	0.232 - 0.235
52-Week Range	0.218 - 0.950
Beta	1.61
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About Poxel

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatoh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 6
• Stock Exchange: Euronext Paris
• Ticker Symbol: POXEL

Financial Performance

In 2023, Poxel's revenue was 1.98 million, an increase of 193.92% compared to the previous year's 674,000. Losses were -35.09 million, 11.8% more than in 2022.